Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1984 1
1985 1
1986 3
1987 2
1988 1
1989 2
1991 3
1992 1
1994 4
1995 5
1996 1
1997 2
1998 1
1999 2
2000 3
2005 1
2007 1
2008 2
2009 2
2010 3
2011 1
2012 3
2013 1
2014 2
2015 3
2016 1
2017 1
2018 8
2019 5
2020 8
2021 22
2022 24
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: shinno y. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI, Yoshida T, Yagishita S, Ohuchi M, Sakiyama N, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Hamada A, Ohe Y. Higashiyama RI, et al. Among authors: shinno y. J Thorac Oncol. 2022 Oct;17(10):1227-1232. doi: 10.1016/j.jtho.2022.06.010. Epub 2022 Jul 3. J Thorac Oncol. 2022. PMID: 35788404
Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N, Kohsaka S, Kurokawa K, Shinno Y, Takeda Nakamura I, Ueno T, Kojima S, Kawazu M, Suehara Y, Ishijima M, Goto Y, Kojima Y, Yonemori K, Hayashi T, Saito T, Shukuya T, Takahashi F, Takahashi K, Mano H. Hasegawa N, et al. Among authors: shinno y. Cancer Sci. 2021 Oct;112(10):4393-4403. doi: 10.1111/cas.15084. Epub 2021 Aug 18. Cancer Sci. 2021. PMID: 34310819 Free PMC article.
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: shinno y. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685 Free article.
Retroperitoneal myofibroblastoma in an 88-year-old male.
Watari S, Ichikawa T, Shiraishi H, Sakuma T, Kubota R, Kusumi N, Tsushima T, Nagakita K, Shinno Y. Watari S, et al. Among authors: shinno y. IJU Case Rep. 2022 Jun 14;5(5):378-382. doi: 10.1002/iju5.12493. eCollection 2022 Sep. IJU Case Rep. 2022. PMID: 36090948 Free PMC article.
Upper Lobe-predominant Autoimmune Pulmonary Alveolar Proteinosis.
Goda M, Takigawa Y, Fujiwara K, Shinno Y. Goda M, et al. Among authors: shinno y. Intern Med. 2023 May 15;62(10):1569-1570. doi: 10.2169/internalmedicine.0226-22. Epub 2022 Oct 12. Intern Med. 2023. PMID: 36223923 Free article. No abstract available.
Performance of Japanese patients in registrational studies.
Goto Y, Arakawa S, Shirasawa M, Higashiyama R, Baba K, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Goto Y, et al. Among authors: shinno y. Jpn J Clin Oncol. 2022 Jan 3;52(1):53-64. doi: 10.1093/jjco/hyab171. Jpn J Clin Oncol. 2022. PMID: 34978326
[Endourology update].
Shinno Y, Morita K, Sasaki Y, Ameda K, Shinohara N, Nonomura K, Koyanagi T, Nantani M, Taniguchi K, Matsuno T. Shinno Y, et al. Hokkaido Igaku Zasshi. 1995 May;70(3):391-6. Hokkaido Igaku Zasshi. 1995. PMID: 7590590 Review. Japanese.
114 results